Brian Gagnon's questions to Profound Medical Corp (PROF) leadership • Q2 2024
Question
Brian Gagnon of Gagnon Securities inquired about the current number of procedures per day performed by top TULSA users and their future expectations with reimbursement. He also asked for details on the new 0.55T interventional MRI systems and sought confirmation that radical prostatectomies are unprofitable for hospitals on CMS patients, which would benefit TULSA.
Answer
CEO Arun Menawat and COO Mathieu Burtnyk stated that roughly 25% of sites are already performing 3-4 procedures per day, a number expected to increase with the new AI modules. Menawat detailed the advantages of the new 0.55T MRIs, including lower weight, smaller footprint, and reduced shielding costs, making them ideal for office or ASC settings. He confirmed that robotic prostatectomy is often a loss-leader for hospitals on Medicare patients, and Profound believes TULSA can offer a break-even or profitable alternative in that setting.